Daniel Spratt, MD

About

Dan Spratt, MD, is a board-certified, international expert in the management of prostate cancer. Dr. Spratt attended Vanderbilt School of Medicine (Nashville, Tennessee) for his medical training and completed his Radiation Oncology residency at Memorial Sloan Kettering Cancer Center (New York, New York). He joined the University of Michigan in 2015, where Dr. Spratt served as the Associate Chair for Clinical Research, the co-Chair for Genitourinary Clinical Trials for the Rogel Cancer Center, and the founding co-Director of the Spine Oncology Program. In addition, Dr. Spratt held leadership roles in the NIH Prostate SPORE and the U10 LAPS grant for cooperative group trials. His accomplishments were numerous, which resulted in his promotion to Full Professor with tenure in 5 years from finishing residency training, the fastest in the University’s history.

In 2021 Dr. Spratt was recruited to serve as the Vincent K. Smith Chair of the Department of Radiation Oncology at University Hospitals Cleveland Medical Center and the Chair of Radiation Oncology at Case Western Reserve University School of Medicine. In 2025 Dr. Spratt became the Associate Chief Scientific Officer and the Medical Director for the Clinical Research Center for University Hospitals.

Dr. Spratt’s clinical expertise encompasses the management of genitourinary cancers (prostate, bladder, kidney and testicular), metastasis-directed radiotherapy and spine stereotactic body radiotherapy. Patients travel from all over the world to seek his expert care for these conditions.

Dr. Spratt’s research expertise centers on the development and validation of prognostic and predictive biomarkers used to personalize treatment of cancer patients while avoiding over- and under-treatment. His work has helped lead to the validation of two commercially used and guideline-endorsed biomarkers in prostate cancer. He has published over 500 peer-reviewed manuscripts, including practice-changing work in the New England Journal of Medicine, JAMA, Lancet and Cell. Dr. Spratt has received federal funding from the NIH, Department of Defense and numerous foundations for his research. He is the principal or co-principal investigator on numerous national multi-center clinical trials.

Dr. Spratt serves as the Chair of the National Comprehensive Cancer Network (NCCN) Prostate Cancer Guidelines, the first radiation oncologist to hold this role; a standing member of the FDA’s Oncology Drug Advisory Committee, the first radiation oncologist to hold this role; Chair for NRG Oncology’s Intact Prostate Cancer Subcommittee; and a member of the National Cancer Institute’s Genitourinary Steering Committee.

While he is proud of his many accomplishments, he is most proud of the transformative team he has assembled at University Hospitals and Case Western Reserve University that continues to push the field forward to new unprecedented heights to help patients around the world.

Awards

2014 – ASTRO’s 56th Annual Basic Science Abstract Award in the Biology
2016 – Association of Residents in Radiation Oncology (ARRO) Teacher of the Year Award
2017 – Annual Clinical Faculty Teacher of the Year Award
2018 – Dean’s Award for Clinical Research
2018 – ASTRO’s Steven Liebel Award
2019 – Graduate Medical Education’s Teacher/Mentor of the Year Award
2019 – Cancer Clinical Investigator Team Leadership Award (CCITLA) National Institutes of Health Award
2020 – Outstanding Clinical Research Award, Rogel Cancer Center